Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB)

Real-world evidence for clinical outcomes and treatment patterns in patients with hormone receptor-positive(HR+)and human epidermal growth factor receptor 2-negative(HER2-)early breast cancer(EBC)in Japan is limited. We aimed to provide recent evidence in this population using the National Database...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 50; no. 12; p. 1283
Main Authors Komatsu, Shuichiro, Kawai, Masaaki, Takada, Masahiro, Nakayama, Takahiro, Masuda, Norikazu, Shiheido, Hirokazu, Cai, Zhihong, Huang, Yu Jing, Kawaguchi, Tsutomu, Tanizawa, Yoshinori
Format Journal Article
LanguageEnglish
Published Japan 01.12.2023
Subjects
Adult
Breast Neoplasms - drug therapy
Breast Neoplasms - surgery
Cyclophosphamide
Female
Gonadotropin-Releasing Hormone
Humans
Japan
Tamoxifen
Young Adult
Japan
Online AccessGet more information

Cover

More Information
Summary:Real-world evidence for clinical outcomes and treatment patterns in patients with hormone receptor-positive(HR+)and human epidermal growth factor receptor 2-negative(HER2-)early breast cancer(EBC)in Japan is limited. We aimed to provide recent evidence in this population using the National Database of Health Insurance Claims and Specific Health Check-ups of Japan(NDB). Adults ≥20 years old who were diagnosed with HR+/HER2- breast cancer and underwent breast resection surgery were followed up. Patient characteristics and treatment patterns were evaluated. Durations of overall post-operative endocrine therapy(ET)and luteinizing hormone-releasing hormone(LH-RH)agonist therapy, and time to metastasis/recurrence after surgery were analyzed using Kaplan-Meier method. Overall, 294,904 patients were included. Cyclophosphamide and tamoxifen were the most common peri-operative chemotherapeutic and ET drugs. Median(95% confidence interval[CI])duration of post-operative ET and LH-RH agonist therapy was 5.01(5.01-5.01)years and 2.13 (2.12-2.14)years, respectively. Five-year cumulative rate(95% CI)of any recurrence was 8.6%(8.5-8.7), visceral metastasis being the most common. Nation-wide treatment patterns were described, which were consistent with guideline recommendations for patients with HR+, HER2- EBC. Further discussion is required to delay metastasis/recurrence and improve clinical outcomes(Fig. 1: Plain language summary of the study).
ISSN:0385-0684